Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?
A strong stock as of late has been Biodesix, Inc. (BDSX). Shares have been marching higher, with the stock up 16.1% over the past month. The stock hit a new 52-week high of $25.51 in the previous session. Biodesix has gained 265.6% since the start of the year compared to the 3.5% move for the Zacks Medical sector and the 2.1% return for the Zacks Medical Services industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on August 5, 2026, Biodesix reported EPS of -$0.71 versus consensus estimate of -$0.86 while it beat the consensus revenue estimate by 2.92%.
For the current fiscal year, Biodesix is expected to post earnings of -$2.68 per share on $111.66 in revenues. This represents a 42.61% change in EPS on a 26.17% change in revenues. For the next fiscal year, the company is expected to earn -$1.66 per share on $132.95 in revenues. This represents a year-over-year change of 38.18% and 19.07%, respectively.
Valuation Metrics
Biodesix may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Biodesix has a Value Score of F. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of B.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Biodesix currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Biodesix meets the list of requirements. Thus, it seems as though Biodesix shares could still be poised for more gains ahead.
How Does BDSX Stack Up to the Competition?
Shares of BDSX have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is PACS Group, Inc. (PACS). PACS has a Zacks Rank of #1 (Strong Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of F.
Earnings were strong last quarter. PACS Group, Inc. beat our consensus estimate by 14.55%, and for the current fiscal year, PACS is expected to post earnings of $2.23 per share on revenue of $5.71 billion.
Shares of PACS Group, Inc. have gained 12% over the past month, and currently trade at a forward P/E of 21.73X and a P/CF of 30.31X.
The Medical Services industry is in the top 36% of all the industries we have in our universe, so it looks like there are some nice tailwinds for BDSX and PACS, even beyond their own solid fundamental situation.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Biodesix, Inc. (BDSX) : Free Stock Analysis Report
PACS Group, Inc. (PACS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
